English

首页 > 新闻中心

亚什兰公布 2018 财年第二季度初步财务业绩,表现超出指导性预测,本年度收益预期上调

发布时间:2018-05-10

·         本季度特种添加剂部门销售额和调整后收益增长强劲

·         鉴于三大业务部门前景均稳健向好,公司上调对 2018 财年收益的指导性预测

·         公司宣布加快特种添加剂部门息税折旧摊销前利润率 (EBITDA) 增长计划


美国肯塔基州卡温顿市,2018 年 5 月 1 日——为广大个人消费品和工业品市场提供优质服务的全球顶尖特种化学品公司亚什兰集团(纽约证交所:ASH)今日公布了 2018 财年第二季度初步1财务业绩:

·         销售额同比增长 21%,达到 9.74 亿美元。

·         公司净收益为 7,300 万美元,持续经营业务收益为 6,600 万美元,相当于摊薄每股收益为 1.04 美元。

·         调整后持续经营业务收入为 6,700 万美元,相当于摊薄每股收益为 1.06 美元,高于 0.80-0.90 美元的指导性预测,这得益于强劲的运营业绩和实际税率降低。

·         调整后息税折旧摊销前利润 (EBITDA) 达 1.79 亿美元,相比去年同期提高 30%。


亚什兰集团董事会主席及首席执行官武威忠 (William A. Wulfsohn) 表示:“三大业务部门的销售额和调整后 EBITDA 均取得强劲增长。特种添加剂部门销售额增长达 19%,其中有机增长达 5%,主要得益于高销量、更优化的产品组合和一贯的定价策略。所有终端市场的业绩均实现提升,制药市场因资产利用计划实现产能提升,以 17% 的销售额增长在各市场中拔得头筹。此外,Pharmachem 业绩继续如期增长,为本季度总业绩作出重大贡献。各市场的广泛增长令该部门调整后 EBITDA 提高 20%,达 1.53 亿美元,调整后 EBITDA 利润率提高 40 个基点,达到 23.7%。复合材料部门销售量上涨,产品组合优化,定价规范严格,加上去年收购的法国工厂带来的效益,推动该部门销售额和收益继续大幅增加。化学中间体和溶剂部门受定价和汇率的积极影响,销售额增长达 18%。”


他还指出:“面对即将开始的下半财年,集团整体销售额和收益表现出强劲势头,三大业务部门均有望实现甚至超越本财年的业绩目标。因此,我们提高了 2018 财年的预期,预计本财年调整后每股收益在 3.30 至 3.50 美元之间,同比增长 35-45%。这一发展势头源于亚什兰为保持最佳业务组合、确保持续增长采取的多项措施,如制定新市场战略,发布新产品,积极兑现亚什兰致力于解决难题的品牌承诺。我们还通过提高资产利用率、加强价值销售和控制成本来提高我们的竞争力。从上半财年业绩报告可以看出,我们在诸多领域取得重大进展,但仍有很大进步空间。希望通过各项计划为第三季度及日后发展提升驱动力。”


亚什兰还于今日公布一项计划,旨在削减整个集团和特种添加剂部门的销售、一般及行政 (SG&A) 成本及生产工厂相关成本共计 1.2 亿美元。根据这一计划:

·         通过成本转移和缩减举措,抵消或降低复合材料业务和德国马尔丁二醇生产工厂的约 7,000 万美元成本。

·         特种化学品部门削减约 5,000 万美元成本,以提高该部门的盈利,加快实现 25-27% 的调整后 EBITDA 利润率。


武威忠表示:“亚什兰正努力进一步精简业务组合,全力以赴发展特种添加剂业务,并借此机会形成更精益、更具竞争力的成本结构。这一计划将推动亚什兰全球团队开展根本性变革,打造全新的团队合作模式。我们相信,除降低成本外,这些举措还将加速决策进程,提高运营效率,助力亚什兰提供更专注的客户服务。我们计划于 2019 自然年年底实现全部运营费用节约目标,从而提高利润率,为股东创造更高价值。”


各业务部门绩效及前景预期


为协助了解亚什兰当前业务绩效,下文将分别介绍亚什兰各业务部门的调整后业绩。本新闻稿表 5 中的 EBITDA 或调整后 EBITDA 已与营业利润进行对账调节。此外,本新闻稿表 7 中的自由现金流和表 8 中的调整后每股收益已经过对账调节。(欲获取各部门更详细的业绩信息,请参阅 ashland.com “Investor Relations” (投资者关系)部分,查看与此次收益发布一并提交给证券交易委员会的演示文稿。)这些调整后结果为非公认会计准则(非 GAAP)财务指标。关于所使用的非 GAAP 财务指标的完整说明,请参阅第6  页“非 GAAP 指标的使用”部分,该部分对这些调整进行了详细介绍。


特种添加剂

·         销售额增长 19%,达到 6.46 亿美元。销售额上涨得益于销售量的强劲表现,产品组合的优化,以及公司所收购 Pharmachem 的贡献。个人护理和粘合剂市场销售额均上升 7%,涂料市场销售额上涨 4%,施工/能源市场上涨 8%。有利的外汇汇率变动对销售额总体增长的贡献为 4%。

·         SG&A 成本上涨 9%。这一指标上涨是受到收购 Pharmachem 和外汇汇率的影响,排除这些影响后,SG&A 有所下降。

·         得益于上述积极因素,调整后 EBITDA 上升 20%,达到 1.53 亿美元,调整后 EBITDA 利润率上升 40 个基点,达到 23.7%。


复合材料

·         销售额上涨 28%,达到 2.38 亿美元。这归功于该部门通过持续专注于优化商业运作,进行价值销售,以及推动北美、南美和印度的业务增长,从而带来强劲的有机增长。

·         调整后 EBITDA 增长 39%,达到 2,500 万美元。


化学中间体和溶剂

·         销售额增长 18%,达到 9,000 万美元,这得益于产品价格持续走强和有利的汇率影响。

·         该季度调整后 EBITDA 为 1,200 万美元,去年同期调整后 EBITDA 约为 500 万美元。

 

资产负债表和现金流

·         总负债为 26 亿美元。

·         净负债为 24 亿美元。

·         本季度,持续经营业务所提供的现金总额为 2,300 万美元,去年同期为 5,800 万美元。

·         自由现金流为 1,300 万美元,去年同期为 1,700 万美元。2018 财年第二季度自由现金流中包含重组支付费用 600 万美元,去年同期自由现金流中包含 1,100 万美元重组支付费用。


前景预期

鉴于各业务部门前景均稳健向好,亚什兰今日将 2018 财年收益指导性预测上调至每股 3.30-3.50 美元。公司还将 2018 财年自由现金流预期调至 2.2 亿美元以上。请参阅下表获取更多关于公司 2018 财年前景预期的信息。


尽管亚什兰提供了调整后 EBITDA、自由现金流和摊薄每股收益的指导性预测,但公司并未重申或提供采用美国一般公认会计原则 (GAAP) 的财务指标预期,或非 GAAP 财务指标预期与最直接可比较的美国 GAAP 指标的对账结果。并未包含此种对账结果的原因是,亚什兰在能力可及范围内无法估计和量化最直接可比较的 GAAP 指标,主要由于对公司未来经营业绩的预测受许多难以预测的因素影响,这些因素不受亚什兰控制且不属于亚什兰日常经营活动的范畴,其中包括各种国内和国际的经济、政治、立法、监管和法律因素。


 

2018 财年初始预期

调整后预期

调整后 EBITDA

 

 

·         特种添加剂

5.60-5.90 亿美元

5.65-5.85 亿美元

·         复合材料

8,500-9,500 万美元

0.90-1.00 亿美元

·         化学中间体和溶剂

4,000-5,000 万美元

5,000-6,000 万美元

·         未分配及其他

3,500-4,500 万美元)

不变

关键运营指标

 

 

·         自由现金流

> 2.20 亿美元

不变

·         调整后每股收益 (EPS)

2.90-3.10 美元

3.30-3.50 美元

公司科目

 

 

·         折旧和摊销

~2.90 亿美元

~3.00 亿美元

·         利息支出

1.25-1.35 亿美元

1.23-1.28 亿美元

·         实际税率

16-20%

13-17%

·         资本支出

1.95-2.05 亿美元

不变

·         摊薄股数

~6,400

不变


亚什兰 2018 财年第三季度调整后摊薄每股收益预期为 0.95-1.05 美元,去年同期摊薄每股收益为 0.83 美元。这一预测基于第三季度实际税率为 17% 的假定。


欲获取亚什兰第二季度的更多财务信息,请参阅与本新闻稿一同发布的演示文稿。


Conference Call Webcast

Ashland will host a live webcast of its second-quarter conference call with securities analysts at 9 a.m. EDT Wednesday, May 2, 2018. The webcast will be accessible through Ashland's website at http://investor.ashland.com. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months.


Use of Non-GAAP Measures

Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA and Adjusted EBITDA provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income and operating income. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA and Adjusted EBITDA exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA and Adjusted EBITDA provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its business units and provide continuity to investors for comparability purposes.


Key items are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland's underlying business performance and trends.      Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor's ability to compare financial performance between reporting periods.


Tax-specific key items are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above.    These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income.       As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland's underlying business performance and trends.


The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.


Adjusted diluted earnings per share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing the diluted earnings per share metric that excludes the effect of the identified key items and tax specific key items.


About Ashland

Ashland Global Holdings Inc. (NYSE: ASH) is a premier global specialty chemicals company serving customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, personal care and pharmaceutical. At Ashland, we are approximately 6,500 passionate, tenacious solvers - from renowned scientists and research chemists to talented engineers and plant operators - who thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com to learn more.


C-ASH


Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance and financial condition, as well as the economy and other future events or circumstances. Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the program to eliminate certain existing corporate and Specialty Ingredients expenses (including the possibility that such cost eliminations may not occur or may take longer to implement than anticipated), the expected divestiture of its Composites segment and for the butanediol (BDO) manufacturing facility in Marl, Germany, and related merchant Intermediates and Solvents (I&S) products (including,

in each case, the possibility that a transaction may not occur or that, if a transaction does occur, Ashland may not realize the anticipated benefits from such transaction), the impact of acquisitions and/or divestitures Ashland has made or may make, including the acquisition of Pharmachem (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); Ashland's ability to generate sufficient cash to finance its stock repurchase plans; the potential that Ashland does not realize all of the expected benefits of the separation of its Valvoline business; the potential that the Tax Cuts and Jobs Act enacted on December 22, 2017, will have a negative impact on Ashland's financial results; and severe weather, natural disasters, cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters). Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements, including, without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.



(1) Preliminary Results

Financial results are preliminary until Ashland's Form 10-Q is filed with the SEC.


(TM) Trademark, Ashland or its subsidiaries, registered in various countries.


FOR FURTHER INFORMATION:

Investor Relations:

Seth A. Mrozek       

+1 (859) 815-3527

samrozek@ashland.com


Media Relations:

Gary Rhodes

+1 (859) 815-3047

glrhodes@ashland.com


Ashland Q2 2018 Financial Tables - FINAL

Ashland Q2 2018 Earnings Presentation for Release Slides - FINAL



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ashland Inc. via Globenewswire


News Provided by Acquire Media